{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:22:54Z","timestamp":1769858574851,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Interindividual variability in epirubicin exposure limits the efficacy of standard chemotherapy dosing based on body surface area (BSA) in breast cancer. This study evaluated a novel liquid-based capillary microsampling technology, True Dose<jats:sup>\u00ae<\/jats:sup>, to enable decentralized therapeutic drug monitoring (TDM). It integrates internal standards (IS) at the blood collection point, enabling the immediate precipitation of proteins and stabilization of analytes. Analytical validation using liquid chromatography-tandem mass spectrometry (LC-MS\/MS) showed that epirubicin signal responses from capillary samples corresponded with those from conventional venous samples, achieving R\u00b2 values of \u2265\u20090.99. Intra-assay coefficient of variation (CV%) improved over time, decreasing from up to 18.6% at T0 to \u2264\u200911% from Day 3 onward, consistent with time-dependent matrix equilibration and improved extraction efficiency. Pre- and post-activation stability studies confirmed analyte integrity for up to 14 days at ambient temperatures. Hematocrit levels ranging from 7 to 18\u00a0g\/dL showed no more than 17% signal variation, confirming matrix stability. In a clinical substudy involving 4 early-stage breast cancer patients, capillary-collected samples (<jats:italic>n<\/jats:italic>\u2009=\u20094 Cap-TD) yielded epirubicin\/doxorubicin ratios that differed by no more than 15% from venous-derived samples;\u00a0interpretation is limited by the small sample size. The findings support the feasibility of the True Dose<jats:sup>\u00ae<\/jats:sup> system as a method for decentralized TDM of anthracycline (epirubicin) chemotherapy. The technology demonstrated analyte stability under room temperature storage for up to 14 days, time-dependent improvement in analytical precision, and minimal hematocrit bias, warranting further investigation in a broader clinical setting.<\/jats:p>\n          <jats:p>Clinical trial identification:\u00a0EudraCT 2017-000641-44 (registered 27 Feb 2017); EUCT 2024-514818-12-00 (CTIS, transitioned from EudraCT). <\/jats:p>","DOI":"10.1038\/s41598-025-20951-5","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T10:45:48Z","timestamp":1759142748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and evaluation of a novel capillary blood collection method for decentralized therapeutic drug monitoring using the True Dose kit"],"prefix":"10.1038","volume":"15","author":[{"given":"Nektarios","family":"Komninos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"De Chiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Checa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Wiklander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Rydberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Hedayati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"13","key":"20951_CR1","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0959-8049(02)00151-X","volume":"38","author":"A Felici","year":"2002","unstructured":"Felici, A., Verweij, J. & Sparreboom, A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur. J. Cancer. 38 (13), 1677\u20131684 (2002).","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"20951_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/clpt.2012.243","volume":"93","author":"JH Beumer","year":"2013","unstructured":"Beumer, J. H. Without therapeutic drug Monitoring, there is no personalized cancer care. Clin. Pharmacol. Ther. 93 (3), 228\u2013230 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"31","key":"20951_CR3","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1200\/JCO.2012.44.2863","volume":"30","author":"JH Beumer","year":"2012","unstructured":"Beumer, J. H., Chu, E. & Salamone, S. J. Body-surface area-based chemotherapy dosing: appropriate in the 21st century? J. Clin. Oncol. 30 (31), 3896\u20133897 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"20951_CR4","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1001\/jamaoncol.2022.4452","volume":"8","author":"JH Beumer","year":"2022","unstructured":"Beumer, J. H., Chu, E. & Salamone, S. J. All optimal dosing roads lead to therapeutic drug Monitoring\u2014Why take the slow lane. JAMA Oncol. 8 (12), 1733\u20131735 (2022).","journal-title":"JAMA Oncol."},{"key":"20951_CR5","unstructured":"(IARC) IAfRoC. Breast Cancer: Fact Sheet. (2021). https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/20-breast-fact-sheet.pdf (accessed May 3, 2025."},{"issue":"3","key":"20951_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"key":"20951_CR7","unstructured":"Socialstyrelsen Cancer Incidence in Sweden 2023 [in Swedish] (The National Board of Health and Welfare (Socialstyrelsen), 2024)."},{"issue":"8","key":"20951_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1634\/theoncologist.12-8-913","volume":"12","author":"RHJ Mathijssen","year":"2007","unstructured":"Mathijssen, R. H. J. et al. Flat-Fixed dosing versus body surface Area\u2013Based dosing of anticancer drugs in adults: does it make a difference? Oncologist 12 (8), 913\u2013923 (2007).","journal-title":"Oncologist"},{"issue":"12 Pt 1","key":"20951_CR9","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1158\/1078-0432.CCR-03-0591","volume":"10","author":"FA de Jong","year":"2004","unstructured":"de Jong, F. A., Mathijssen, R. H., Xie, R., Verweij, J. & Sparreboom, A. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin. Cancer Res. 10 (12 Pt 1), 4068\u20134071 (2004).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"20951_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/cpt.1989","volume":"109","author":"SL Groenland","year":"2021","unstructured":"Groenland, S. L. et al. Exposure-response analyses of anaplastic lymphoma kinase inhibitors Crizotinib and alectinib in Non-Small cell lung cancer patients. Clin. Pharmacol. Ther. 109 (2), 394\u2013402 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"20951_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40262-017-0555-z","volume":"57","author":"L Klopp-Schulze","year":"2018","unstructured":"Klopp-Schulze, L. et al. Exploiting Pharmacokinetic models of Tamoxifen and Endoxifen to identify factors causing subtherapeutic concentrations in breast cancer patients. Clin. Pharmacokinet. 57 (2), 229\u2013242 (2018).","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"20951_CR12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00228-019-02704-2","volume":"75","author":"SL Groenland","year":"2019","unstructured":"Groenland, S. L., Mathijssen, R. H. J., Beijnen, J. H., Huitema, A. D. R. & Steeghs, N. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur. J. Clin. Pharmacol. 75 (9), 1309\u20131318 (2019).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"20951_CR13","doi-asserted-by":"crossref","unstructured":"Groenland, S.L. et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann. Oncol. 33 (10), 1071\u20131082 (2022).","DOI":"10.1016\/j.annonc.2022.06.010"},{"issue":"24","key":"20951_CR14","doi-asserted-by":"publisher","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-20-4555","volume":"27","author":"SL Groenland","year":"2021","unstructured":"Groenland, S. L. et al. Precision dosing of targeted therapies is ready for prime time. Clin. Cancer Res. 27 (24), 6644\u20136652 (2021).","journal-title":"Clin. Cancer Res."},{"key":"20951_CR15","doi-asserted-by":"publisher","first-page":"1348112","DOI":"10.3389\/fphar.2024.1348112","volume":"15","author":"WS Liang","year":"2024","unstructured":"Liang, W. S. et al. Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine. Front. Pharmacol. 15, 1348112 (2024).","journal-title":"Front. Pharmacol."},{"key":"20951_CR16","doi-asserted-by":"publisher","first-page":"1053211","DOI":"10.3389\/fonc.2022.1053211","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Martin, J. H., Yan, M. & Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs. Front. Oncol. 12, 1053211 (2022).","journal-title":"Front. Oncol."},{"issue":"2","key":"20951_CR17","first-page":"191","volume":"23","author":"JD Kawedia","year":"2019","unstructured":"Kawedia, J. D., Kalariya, N., Gulbis, A. M., Andersson, B. S. & Myers, A. L. Pharmacokinetics: unique challenges in blood monitoring for oncology nurses. Clin. J. Oncol. Nurs. 23 (2), 191\u2013196 (2019).","journal-title":"Clin. J. Oncol. Nurs."},{"issue":"5","key":"20951_CR18","doi-asserted-by":"publisher","first-page":"e70056","DOI":"10.1002\/bmc.70056","volume":"39","author":"M Meertens","year":"2025","unstructured":"Meertens, M., Rosing, H., Steeghs, N., Beijnen, J. H. & Huitema, A. D. R. Advancing therapeutic drug monitoring for oral targeted anticancer drugs: from Hospital-Based towards Home-Sampling. Biomed. Chromatogr. 39 (5), e70056 (2025).","journal-title":"Biomed. Chromatogr."},{"issue":"2","key":"20951_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.14372","volume":"87","author":"BD Menz","year":"2021","unstructured":"Menz, B. D. et al. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br. J. Clin. Pharmacol. 87 (2), 227\u2013236 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"20951_CR20","doi-asserted-by":"crossref","unstructured":"Meertens, M. et al. Clinical application of volumetric absorptive microsampling for therapeutic drug monitoring of oral targeted anticancer drugs. Ther. Drug Monit. (2025).","DOI":"10.1097\/FTD.0000000000001315"},{"issue":"15","key":"20951_CR21","first-page":"825","volume":"16","author":"S Tripathy","year":"2024","unstructured":"Tripathy, S. et al. Patient-centric microsampling for abrocitinib pharmacokinetics: multiple-analytes assay bridging using Tasso device. Bioanalysis 16 (15), 825\u2013834 (2024).","journal-title":"Bioanalysis"},{"issue":"4","key":"20951_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1208\/s12248-024-00947-1","volume":"26","author":"L Boffel","year":"2024","unstructured":"Boffel, L. et al. Self-Sampling by adolescents at home: assessment of the feasibility to successfully collect blood microsamples by inexperienced individuals. Aaps j. 26 (4), 75 (2024).","journal-title":"Aaps j."},{"issue":"4","key":"20951_CR23","first-page":"288","volume":"27","author":"R Zakaria","year":"2016","unstructured":"Zakaria, R., Allen, K. J., Koplin, J. J., Roche, P. & Greaves, R. F. Advantages and challenges of dried blood spot analysis by mass spectrometry across the total testing process. Ejifcc 27 (4), 288\u2013317 (2016).","journal-title":"Ejifcc"},{"issue":"6","key":"20951_CR24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/17576180.2025.2477976","volume":"17","author":"A Kocur","year":"2025","unstructured":"Kocur, A. & Pawi\u0144ski, T. Microsampling techniques and patient-centric therapeutic drug monitoring of immunosuppressants. Bioanalysis 17 (6), 413\u2013427 (2025).","journal-title":"Bioanalysis"},{"key":"#cr-split#-20951_CR25.1","unstructured":"Hedayati, E., Rydberg, P. & Hedayati, D. Device. WO 2025\/036981 A1. World Intellectual Property Organization"},{"key":"#cr-split#-20951_CR25.2","unstructured":"2025-02-20.Assignee: True Dose AB. Application No.: PCT\/EP2024\/073021. IPC: A61B 5\/15. (WIPO, 2025)."},{"issue":"10179","key":"20951_CR26","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","volume":"393","author":"Increasing the dose","year":"2019","unstructured":"Increasing the dose. Intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37\u2008298 women with early breast cancer in 26 randomised trials. Lancet 393 (10179), 1440\u20131452 (2019).","journal-title":"Lancet"},{"issue":"9814","key":"20951_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto, R. et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379 (9814), 432\u2013444 (2012).","journal-title":"Lancet"},{"key":"20951_CR28","unstructured":"Agency, E. M. ICH Guideline M10 on Bioanalytical Method Validation: Step 5. Amsterdam, The Netherlands (2022)."},{"issue":"8","key":"20951_CR29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s42452-019-0778-8","volume":"1","author":"H Sharma","year":"2019","unstructured":"Sharma, H., Navalkar, A., Maji, S. K. & Agrawal, A. Analysis of drug\u2013protein interaction in bio-inspired microwells. SN Appl. Sci. 1 (8), 819 (2019).","journal-title":"SN Appl. Sci."},{"key":"20951_CR30","doi-asserted-by":"publisher","first-page":"1308632","DOI":"10.3389\/fphys.2023.1308632","volume":"14","author":"S Biagiotti","year":"2023","unstructured":"Biagiotti, S., Perla, E. & Magnani, M. Drug transport by red blood cells. Front. Physiol. 14, 1308632 (2023).","journal-title":"Front. Physiol."},{"key":"20951_CR31","doi-asserted-by":"crossref","unstructured":"Tran, L. N. T., Gonz\u00e1lez-Fern\u00e1ndez, C. & Gomez-Pastora, J. Impact of different red blood cell storage solutions and conditions on cell function and viability: A systematic review. Biomolecules  14(7), 813. (2024).","DOI":"10.3390\/biom14070813"},{"key":"20951_CR32","doi-asserted-by":"crossref","unstructured":"Sahoo, J., Mahapatra, S., Sahoo, B. B. & Sahoo, N. Changes in hematological and biochemical parameters and rate of hemolysis during the storage of packed RBC units: A prospective study. J. Lab.  Phys.  17.","DOI":"10.25259\/JLP_212_2024"},{"key":"20951_CR33","unstructured":"Snellstr\u00f6m, J. Quantification of Cytotoxic Drugs in Human Blood: Method Development For Personalized Cancer Medicine [Master\u2019s Thesis].   (Stockholm University, 2016)."},{"issue":"2","key":"20951_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jpp\/rgad104","volume":"76","author":"M Shafiei","year":"2024","unstructured":"Shafiei, M. et al. Comparison of capecitabine concentrations determined by microsampling versus plasma concentrations for therapeutic drug monitoring: a pilot study. J. Pharm. Pharmacol. 76 (2), 86\u201392 (2024).","journal-title":"J. Pharm. Pharmacol."},{"issue":"5-6","key":"20951_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/ansa.202300011","volume":"4","author":"MU Thangavelu","year":"2023","unstructured":"Thangavelu, M. U., Wouters, B., Kindt, A., Reiss, I.K.M. & Hankemeier, T. Blood microsampling technologies: innovations and applications in 2022. Anal. Sci. Adv. 4 (5-6), 154\u2013180 (2023).","journal-title":"Anal. Sci. Adv."},{"issue":"1","key":"20951_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/ph17010063","volume":"17","author":"M Radovanovic","year":"2024","unstructured":"Radovanovic, M., Galettis, P., Flynn, A., Martin, J. H. & Schneider, J. J. Paclitaxel and therapeutic drug monitoring with microsampling in clinical practice. Pharmaceuticals 17 (1), 63 (2024).","journal-title":"Pharmaceuticals"},{"key":"20951_CR37","doi-asserted-by":"publisher","first-page":"116007","DOI":"10.1016\/j.jpba.2024.116007","volume":"242","author":"M Mazzarino","year":"2024","unstructured":"Mazzarino, M. et al. Liquid vs dried blood matrices: application to longitudinal monitoring of androstenedione, testosterone, and IGF-1 by LC-MS-based techniques. J. Pharm. Biomed. Anal. 242, 116007 (2024).","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"5","key":"20951_CR38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/jnci\/djad042","volume":"115","author":"RD Harvey","year":"2023","unstructured":"Harvey, R. D. The earlier the better? Or better late than never? Dose optimization in oncology. JNCI: J. Natl. Cancer Inst. 115 (5), 485\u2013487 (2023).","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"16","key":"20951_CR39","doi-asserted-by":"publisher","first-page":"eads0265","DOI":"10.1126\/sciadv.ads0265","volume":"11","author":"M Corsi","year":"2025","unstructured":"Corsi, M. et al. In vivo and in situ monitoring of doxorubicin pharmacokinetics with an implantable bioresorbable optical sensor. Sci. Adv. 11 (16), eads0265 (2025).","journal-title":"Sci. Adv."},{"key":"20951_CR40","doi-asserted-by":"crossref","unstructured":"Alexandre, J. et al. Intra-individual dose escalation of abiraterone according to its plasma exposure in patients with progressive metastatic Castration-Resistant prostate cancer: results of the OPTIMABI trial. Clin. Pharmacokinet. (2024).","DOI":"10.1007\/s40262-024-01396-x"},{"issue":"12","key":"20951_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/separations9120403","volume":"9","author":"NF El Azab","year":"2022","unstructured":"El Azab, N. F., Binjubair, F. A., Al-Rashood, S. T., Okeil, S. & El Zahar, N. M. Simultaneous quantification of a neoadjuvant treatment used in locally advanced breast cancer using an Eco-Friendly UPLC-MS\/MS method: A Pharmacokinetic study in rat plasma. Separations 9 (12), 403 (2022).","journal-title":"Separations"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20951-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20951-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20951-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T22:03:50Z","timestamp":1759183430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20951-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20951"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20951-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Elham Hedayati receives research funding from Roche and Pierre Fabre, all paid to Karolinska University Hospital. Elham Hedayati and Per Rydberg are co-founders of True Dose AB and have an ownership interest (including patents) in the company. Nektarios Komninos and Serena De Chiara are employed by True Dose AB. Antonio Checa and Oscar Wiklander declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics Review Committee Dnr: 20I5\/12335-3I\/2 with following amendment 2019-02745 and 2024-02661-0.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"33331"}}